Pretomanid

From WikiMD.org
Jump to navigation Jump to search

Pretomanid

Pretomanid (pronunciation: preh-toh-MAH-nid) is a medication used in the treatment of tuberculosis, specifically multi-drug resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB). It is typically used in combination with bedaquiline and linezolid.

Etymology

The name "Pretomanid" is derived from the organization that developed it, the non-profit Global Alliance for TB Drug Development (TB Alliance). The "preto" part of the name is an acronym for "PA-824" (the compound's original designation), "resistant," "TB," and "optimized." The "manid" part of the name is a common suffix for drugs in the nitroimidazole class, to which pretomanid belongs.

Usage

Pretomanid is used in combination with other drugs to treat certain types of drug-resistant tuberculosis. It is part of a regimen for adults with extensively drug-resistant tuberculosis (XDR-TB), or with multi-drug resistant tuberculosis (MDR-TB) who are treatment-intolerant or non-responsive.

Mechanism of Action

Pretomanid is a nitroimidazole antimycobacterial drug. It inhibits the synthesis of mycolic acids, essential components of the mycobacterial cell wall. This results in the death of the mycobacterium tuberculosis bacteria.

Side Effects

Common side effects of pretomanid include nausea, vomiting, headache, increased liver enzymes, and rash. Severe side effects may include QT prolongation and liver toxicity.

Related Terms

External links

Esculaap.svg

This WikiMD article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski